INTRODUCTION AND OBJECTIVES: Penile duplex Doppler ultrasound (PDDU) with intracavernosal injection (ICI) with erectogenic agents is commonly used to evaluate vascular parameters in men with erectile dysfunction (ED). Recent studies have suggested significant variability in outcomes based on ICI dosing protocols, suggesting a need for standardization of injection protocols. Given a lack of literature on this topic, we sought to identify predictors for increased need of ICI dosing to achieve adequate rigidity at the time of PDDU.
METHODS: A retrospective chart review was performed of all patients undergoing PDDU for evaluation of ED from January 2014 to November 2015. At the time of PDDU, men received a combination of papaverine(30 mg/mL), phentolamine(1 mg/mL), and alprostadil(10 mcg/mL) in 0.1 mL increments until an erection sufficient for penetration was achieved or 1.0 cc was administered. Clinicopathologic and demographic variables were reviewed, and univariate and multivariate analyses were used to identify characteristics associated with increased erectogenic requirements.
RESULTS: A total of 262 men (mean age 53;) underwent PDDU during the study period. Mean IIEF-6 score was 12.4 (SD 10.2), and a mean 2.1 injections (SD 1.1) with 0.34 cc (SD 0.34) were administered. On multivariate analysis, lower IIEF-ED domain score (p<0.01), coronary disease (p¼0.03), and diabetes (p¼0.01) were associated with increased requirement for erectogenic medications.
CONCLUSIONS: Patients with lower IIEF scores, coronary disease, and diabetes mellitus may require higher volumes of erectogenic medications at the time of PDDU. This information may help to create standardized and efficient protocols for repeated dosing regimen.
Source of Funding: NONE

MP84-02 UTILITY OF 2D PHOTOGRAPHY IN THE ASSESSMENT OF PENILE CURVATURE IN MEN WITH PEYRONIE'S DISEASE (PD): THE GOSOFT STUDY
INTRODUCTION AND OBJECTIVES: Curvature assessment (CA) in Peyronie's disease (PD) is a critical step in the evaluation of the PD patient. Assessment using combined intracavernosal injection and goniometry (IG) is the standard approach. Aim: to evaluate the utility of novel software (GoSoft) for the measurement of the PD deformity.
METHODS: Population: men with PD, who had a CA using IG. A rigid erection was an inclusion criterion for inclusion in this analysis. Degree of curvature was measured with a goniometer, simultaneously a photograph was taken. The photo was analyzed using GoSoft software by three observers at different time points, each being blinded to the goniometer assessment. The primary outcome was to compare the inter-observer and intra-observer reliability of GoSoft. We also aimed to compare the concordance between GoSoft and goniometry. We compare correlation for curvature 45 degrees and for > 45 degrees. We accepted a variability of 5 degrees and considered an under and over-estimation if the difference was >5 degrees.
RESULTS: 53 subjects were included. The intra-observer reliability was excellent, representing a high correlation ( r¼0.96 to 0.98, p<0.001) with a variance between means of 1.3AE0.6 degrees. The inter-observer reliability was also high (r¼0.89 to 0.95, p<0.001) ( Figure  1 ) with a variance between means of 2.2AE1 degrees. The Pearson correlation coefficients (r) between the goniometer and GoSoft for each rater were: Rater 1: r¼0.75, p<0.001; Rater 2: r¼0.73, p<0.001; and Rater 3: r¼0.80, p<0.001. This indicates strong agreement, but also suggests variability between the types of measurement. For the three raters, when comparing GoSoft to the goniometer, GoSoft accurately measured (within AE5 degrees) 45% of the curvatures, underestimated it by >5 degrees in 25% of the curvatures, and overestimated it by >5 degrees in 30% of the curvatures. The correlation appears to be higher for greater curvatures. For curvature 45 degrees, the correlations between goniometer and GoSoft ranged from: r¼0.41-0.47, p¼0.03; while, for curvatures > 45 degrees, the correlations ranged from: r¼0.59-0.65, p<0.01.
CONCLUSIONS: GoSoft assessment is consistent with goniometry. The excellent reliability and reproducibility might provide a more standardized instrument for CA in men with PD.
Source of Funding: none
MP84-03 DEVELOPMENT OF A CUT-OFF FOR THE PEYRONIE'S DISEASE QUESTIONNAIRE (PDQ) BOTHER SCORE
Jean-Etienne Terrier*, Christian J Nelson, John P Mulhall, New York City, NY INTRODUCTION AND OBJECTIVES: The Peyronie's Disease Questionnaire (PDQ is a validated self-reported questionnaire that measures the impact and severity of Peyronie's Disease (PD) in 3 domains, including Symptom Bother (6 items, score range 0-16). Mean baseline bother score in the IMPRESS trials was 8 (7.8AE3.7). However, the clinical significance of the PDQ bother score has not been evaluated. We aimed to find the optimal PDQ symptom bother score cut-off predicting the presence of clinical bother and distress.
METHODS: Men with PD completed a series of validated questionnaires at initial consultation, including the PDQ, the Center for Epidemiological Studies-Depression scale (CESD), and the Self-Esteem and Relationship questionnaire (SEAR). We used a receiver operating characteristic (ROC) curve to determine the optimal cutoff score of PDQ bother by separately predicting: (1) depressive symptoms as defined as a score of !16 on the CESD (2) low sexual self-esteem defined as a score of 35 on the SEAR (the score reported by those with severe ED) and (3) the combination of depressive symptoms and low sexual self-esteem. The Youden index was used to determine the optimal cut-off maximizing both sensitivity and specificity.
RESULTS: The mean age of the 204 men was 56AE12 years of age. 82% of the sample had a partner, with an average length of relationship of 16AE14 years. The mean duration of PD was 16AE21 months and the average curvature was 39AE20 degrees. When using depressive symptoms (CESD) as the criterion, the ROC curve analysis produced an area under the curve (AUC) of 0.61 (p¼0.04), indicating a cutoff score of 8, which produced the best sensitivity (0.61) and specificity (0.58). When using low sexual self-esteem (SEAR) as the criterion, the ROC curve analysis produced an AUC of 0.70 (p¼0.001), and indicated a cut-off score of 9 producing the optimum sensitivity (0.67) and specificity (0.69). The combination of both criteria failed to produce a significant AUC (0.48, p¼0.56). Since using sexual self-esteem as the criterion produced better AUC and higher sensitivity and specificity, the cut-off score of 9 is suggested.
CONCLUSIONS: A bother score of 9 on the PDQ appears to represent the optimal cut-off score indicating clinically significant bother. In our opinion, such a score warrants a consideration to refer the patient to a mental health professional. The database includes detailed information on demographics, laboratory testing, medications, and comorbid conditions as well as assessments of ED using the Brief Male Sexual Inventory (BMSI) beginning in 2002. Subsequent BMSI questionnaires were completed in 2004, 2006, and 2009 . Men without a sexual partner or those with prior pelvic surgery were excluded. Multivariable modeling was performed to determine factors associated with BMSI scores at the 2002 time point. Significant variables were then included in a weighted, stepwise scoring system to assess the predictability of loss of erectile function over time.
Source of
RESULTS: 937 patients met inclusion criteria, with a mean age of 61 years (SD 8.7). Mean BMSI scores in 2002 , 2004 , 2006 , and 2009 were 7.4 (3.6), 6.9 (3.7), 6.6 (3.8), and 6.0 (3.9), respectively. Multivariate analysis revealed that increasing age (parameter estimate [PE] -0.2 / year over age 40), arterial disease (myocardial infarction, stroke, coronary artery disease; PE -0.7), diabetes (PE -0.7), insulin use (PE -2.0), and beta blocker (PE -0.6) were all associated with a decreased BMSI score (p<.05). The combination of significant factors into a predictive model demonstrated an overall r-squared value of 0.30, suggesting that only 30% of the variability in BMSI scores over time could be accounted for using these factors. In contrast, the use of the BMSI 2002 results demonstrated an r-squared value of 0.50, suggesting that baseline erectile function is a superior predictor for future ED compared to assessments of comorbid conditions and medication use.
CONCLUSIONS: While multiple comorbidities and medications are associated with ED, they fail to produce a predictive model superior
